Equillium, Inc. (NASDAQ:EQ) Short Interest Update

Equillium, Inc. (NASDAQ:EQ) saw a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 672,300 shares, an increase of 620.6% from the January 31st total of 93,300 shares. Currently, 3.9% of the shares of the company are short sold. Based on an average daily volume of 771,000 shares, the days-to-cover ratio is currently 0.9 days.

Equillium Trading Up 0.2 %

Shares of EQ traded up $0.00 during trading hours on Friday, reaching $0.77. The company had a trading volume of 34,616 shares, compared to its average volume of 1,202,720. The firm has a 50 day simple moving average of $0.74 and a 200-day simple moving average of $0.82. Equillium has a 12-month low of $0.49 and a 12-month high of $2.99. The company has a market capitalization of $27.10 million, a price-to-earnings ratio of -5.46 and a beta of 1.79.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Equillium stock. Takeda Pharmaceutical Co. Ltd. bought a new stake in Equillium, Inc. (NASDAQ:EQ) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,824,977 shares of the company’s stock, valued at approximately $1,369,000. Equillium comprises about 5.2% of Takeda Pharmaceutical Co. Ltd.’s portfolio, making the stock its 4th biggest holding. Takeda Pharmaceutical Co. Ltd. owned 5.15% of Equillium as of its most recent filing with the Securities & Exchange Commission. 27.05% of the stock is currently owned by institutional investors.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.